Irvine-based eye drug developer Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Dr. José Trevejo as Chief Medical Officer.
According to the company, Dr. Trevejo brings some 20 years of experience in developing novel therapies for serious diseases, previously holding leadership roles at Rocket Pharmaceuticals, SmartPharm, Cyclerion Therapeutics, and others.
Trevejo’s leadership will be “highly valued” as Tarsus advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs, including a novel anti-parasitic platform, the company said. If “results are positive,” Tarsus is aiming to submit a New Drug Application for the TP-03 later this year.
“Dr. Trevejo’s leadership in drug development and clinical trials will be instrumental in advancing TP-03 towards FDA approval as well as expanding our broader pipeline,” Tarsus Pharmaceuticals Chief Executive Dr. Bobak Azamian said in a statement released today.
